Creative Planning
ACAD icon

Creative Planning’s Acadia Pharmaceuticals ACAD Stock Holding History

Creative Planning’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,000
Closed -$18K – 3751
2014
Q1 		$18K Buy
+4,000
New +$101K ﹤0.01% 2432

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Creative Planning's ACAD Position: Q1 2026 in Review

Creative Planning increased its Acadia Pharmaceuticals (ACAD) stake by 7.8% in Q1 2026, buying an estimated $82.5K and bringing the position to 47,485 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

Creative Planning first reported a position in ACAD in Q2 2013 and has held it in 46 quarters since. The position peaked at $2.18M in Q4 2017. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Creative Planning held 47,485 shares of Acadia Pharmaceuticals worth $1.06M as of Q1 2026.
  • Creative Planning bought 3,454 Acadia Pharmaceuticals shares in Q1 2026, an estimated $82.5K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2411 holding.
  • Creative Planning first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
  • Creative Planning's Acadia Pharmaceuticals position peaked at $2.18M in Q4 2017.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.